1Reynolds S & Quinn T (2010) Setting the stage: current state of affairs and major challenges. Clin Infect Dis 50, Suppl. 3, S71–S76.
5de Béthune MP (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res 85, 75–90.
6McLeod GX & Hammer SM (1992) Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy. Hosp Pract 27, 14–25.
7Shafer RW & Vuitton DA (1999) Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother 53, 73–86.
8De Clercq E (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 38, 153–179.
9Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22, 685–708.
11Wynn GH, Zapor MJ, Smith BH, et al. (2004) Antiretrovirals, part 1: overview, history, and focus on protease inhibitors. Psychosomatics 45, 262–270.
12Greenberg ML & Cammack N (2004) Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54, 333–340.
13Dorr P, Westby M, Dobbs S, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Ch 49, 4721–4732.
14De Clercq E (2010) Antiretroviral drugs. Curr Opin Pharmacol 10, 507–515.
15Dubé MP, Johnson DL, Currier JS, et al. (1997) Protease inhibitor-associated hyperglycaemia. Lancet 350, 713–714.
16Deeks SG (1997) HIV-1 protease inhibitors. A review for clinicians. JAMA 227, 145–153.
17Hengel RL, Watts NB & Lennox JL (1997) Benign symmetric lipomatosis associated with protease inhibitors. Lancet 350, 1596.
18Roth VR, Kravcik S & Angel JB (1998) Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 27, 65–67.
19Viraben R & Aquilina C (1998) Indinavir-associated lipodystrophy. AIDS 12, F37–F39.
20Carr A, Samaras K, Burton S, et al. (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51–F58.
21Mallon PW (2007) Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev 9, 3–15.
22Omolayo O & Sealy PL (2008) HIV lipodystrophy syndrome. Hosp Physician 44, 7–14.
23Lichtenstein K, Balasubramanyam A, Sekhar R, et al. (2007) HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther 4, 16.
24Worm SW, Friis-Møller N, Bruyand M, et al. (2010) High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 24, 427–435.
25Samaras K, Wand H, Law M, et al. (2007) Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria. Diabetes Care 30, 113–119.
27Behrens G, Dejam A, Schmidt H, et al. (1999) Impaired glucose tolerance, β cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13, F63–F70.
28Brown TT, Cole SR, Li X, et al. (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 165, 1179–1184.
29Masiá M, Padilla S, García N, et al. (2010) Endothelial function is impaired in HIV-infected patients with lipodystrophy. Antivir Ther 15, 101–110.
30Friis-Møller N, Sabin CA, Weber R, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349, 1993–2003.
31Salyer J, Lyon DE, Settle J, et al. (2006) Coronary heart disease risks and lifestyle behaviors in persons with HIV infection. J Assoc Nurses AIDS Care 17, 3–17.
32Mondy K, Overton E, Grubb J, et al. (2007) Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 44, 726–734.
33Vittecoq D, Escaut L, Chironi G, et al. (2003) Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 17, Suppl. 1, S70–S76.
34Matetzky S, Domingo M, Kar S, et al. (2003) Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 163, 457–460.
35Bozzette SA, Ake CF, Tam HK, et al. (2008) Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 47, 338–341.
36Khunnawat C, Mukerji S, Havlichek D Jr, et al. (2008) Cardiovascular manifestations in human immunodeficiency virus-infected patients. Am J Cardiol 102, 635–642.
37Friis-Møller N, Thiébaut R, Reiss P, et al. (2010) Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 17, 491–501.
38Guaraldi G, Zona S, Alexopoulos N, et al. (2009) Coronary aging in HIV-infected patients. Clin Infect Dis 49, 1756–1762.
39American Dietetic Association (2010) Position of the American Dietetic Association: nutrition intervention and human immunodeficiency virus infection. J Am Diet Assoc 110, 1105–1119.
40Hendricks KM, Dong KR, Tang AM, et al. (2003) High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition. Am J Clin Nutr 78, 790–795.
41Shah M, Tierney K, Adams-Huet B, et al. (2005) The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy. HIV Med 6, 291–298.
42Leite LHM & Sampaio ABMM (2010) Dietary calcium, dairy food intake and metabolic abnormalities in HIV-infected individuals. J Hum Nutr Diet 23, 535–543.
43Hadigan C, Jeste S, Anderson EJ, et al. (2001) Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clin Infect Dis 33, 710–717.
44Tsiodras S, Poulia K-A, Yannakoulia M, et al. (2009) Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. Metabolism 58, 854–859.
45Turčinov D, Stanley C, Rutherford G, et al. (2009) Adherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy. Eur J Epidemiol 24, 267–274.
46Jacobson DL, Tang AM, Spiegelman D, et al. (2006) Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 43, 458–466.
47Sobieszczyk ME, Hoover DR, Anastos K, et al. (2008) Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 48, 272–280.
48Tien PC, Cole SR, Williams CM, et al. (2003) Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 34, 461–466.
49Norris A & Dreher HM (2004) Lipodystrophy syndrome: the morphologic and metabolic effects of antiretroviral therapy in HIV infection. J Assoc Nurses AIDS Care 15, 46–64.
50Benn P, Ruff C, Cartledge J, et al. (2003) Overcoming subjectivity in assessing facial lipoatrophy: is there a role for three-dimensional laser scans? HIV Med 4, 325–331.
51Carter V, Hoy J, Bailey M, et al. (2001) The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2, 174–180.
52Boufassa FDA, Lascaux AS, Meyer L, et al. (2001) Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials 2, 339–345.
53Chêne G, Angelini E, Cotte L, et al. (2002) Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 34, 649–657.
54Galli M, Cozzi-Lepri A, Ridolfo AL, et al. (2002) Incidence of adipose tissue alterations in first-line antiretroviral therapy: The LipoICoNa Study. Arch Intern Med 162, 2621–2628.
55Galli M, Veglia F, Angarano G, et al. (2003) Gender differences in antiretroviral drug-related adipose tissue alterations: women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 34, 58–61.
56Miller J, Carr A, Emery S, et al. (2003) HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 4, 293–301.
57Puttawong S, Prasithsirikul W & Vadcharavivad S (2004) Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai 87, 605–611.
58Young J, Rickenbach M, Weber R, et al. (2005) Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV Cohort Study. Antivir Ther 10, 73–81.
59Mutimura EM, Stewart AP, Rheeder PMD, et al. (2007) Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 46, 451–455.
60Nguyen A, Calmy A, Schiffer V, et al. (2008) Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006. HIV Med 9, 142–150.
61Seminari E, Tinelli C, Minoli L, et al. (2002) Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients. Antivir Ther 7, 175–180.
62Kalyanasundaram AP, Jacob SM, Hemalatha R, et al. (2012) Prevalence of lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in Rural South India. J Int Assoc Physicians AIDS Care (Chic) 11, 329–334.
63Saint-Marc T, Partisani M, Poizot-Martin I, et al. (2000) Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14, 37–49.
64Thiébaut R, Daucourt V, Mercié P, et al. (2000) Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 31, 1482–1487.
65Lichtenstein KA, Ward DJ, Moorman AC, et al. (2001) Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15, 1389–1398.
66Heath KV, Singer J, O'Shaughnessy MV, et al. (2002) Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr 31, 211–217.
67Mauss S, Corzillius M, Wolf E, et al. (2002) Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 3, 49–55.
68Paton NI, Earnest A, Ng YM, et al. (2002) Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis 35, 1244–1249.
69Lichtenstein KA, Delaney KM, Armon C, et al. (2003) Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 32, 48–56.
70Pujari SN, Dravid AM, Naik E, et al. (2005) Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 39, 199–202.
71van Griensven J, De Naeyer L, Mushi T, et al. (2007) High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 101, 793–798.
72Walmsley S, Cheung A, Fantus G, et al. (2008) A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy. HIV Clin Trials 9, 314–323.
73Jevtovic D, Dragovic G, Salemovic D, et al. (2009) The metabolic syndrome, an epidemic among HIV-infected patients on HAART. Biomed Pharmacother 63, 337–342.
74Mercier S, Gueye NFN, Cournil A, et al. (2009) Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case–control study. J Acquir Immune Defic Syndr 51, 224–230.
75Zannou DM, Denoeud L, Lacombe K, et al. (2009) Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther 14, 371–380.
76Gervasoni C, Ridolfo AL, Trifiro G, et al. (1999) Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13, 465–471.
77Goujard C, Boufassa F, Deveau C, et al. (2001) Incidence of clinical lipodystrophy in HIV-1-infected patients treated during primary infection. AIDS 15, 282–284.
78Heath KV, Hogg RS, Chan KJ, et al. (2001) Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 15, 231–239.
79Martínez E, Mocroft A, García-Viejo MA, et al. (2001) Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357, 592–598.
80Bernasconi E, Boubaker K, Junghans C, et al. (2002) Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 31, 50–55.
81Savès M, Raffi F, Capeau J, et al. (2002) Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 34, 1396–1405.
82Carr A, Emery S, Law M, et al. (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case–control study. Lancet 361, 726–735.
83Galli M, Ridolfo AL, Adorni F, et al. (2003) Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Antivir Ther 8, 347–354.
84Fellay J, Ledergerber B, Bernasconi E, et al. (2001) Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358, 1322–1327.
85van der Valk M, Gisolf EH, Reiss P, et al. (2001) Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 15, 847–855.
86National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421.
87Jericó C, Knobel H, Montero M, et al. (2005) Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 28, 132–137.
88Elgalib A, Aboud M, Kulasegaram R, et al. (2011) The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. Curr Med Res Opin 27, 63–69.
90Gkrania-Klotsas E & Klotsas A-E (2007) HIV and HIV treatment: effects on fats, glucose and lipids. Br Med Bull 84, 49–68.
91Grundy SM, Brewer HB Jr, Cleeman JI, et al. (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433–438.
93Han SH, Zhou J, Saghayam S, et al. (2011) Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocr J 58, 475–484.
94Wanke C, Polsky B & Kotler D (2002) Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDS 16, 375–388.
95Carr A, Law M &
HIV Lipodystrophy Case Definition Study Group
(2003) An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 33, 571–576.
96Fontdevila J, Serra-Renom JM, Raigosa M, et al. (2008) Assessing the long-term viability of facial fat grafts: an objective measure using computed tomography. Aesthet Surg J 28, 380–386.
97Guaraldi G & Baraboutis I (2009) Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities. J Antimicrob Chemother 64, 437–440.
98Carr A, Samaras K, Thorisdottir A, et al. (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353, 2093–2099.
99Safrin S & Grunfeld C (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS 13, 2493–2505.
100Saint-Marc T, Partisani M, Poizot-Martin I, et al. (1999) A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13, 1659–1667.
101Grinspoon S, Corcoran C, Miller K, et al. (1997) Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 82, 1332–1337.
102Engelson ES, Kotler DP, Tan Y, et al. (1999) Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 69, 1162–1169.
103Bergersen B, Sandvik L, Ellingsen I, et al. (2005) Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive. HIV Med 6, 260–267.
104Nolan D, Hammond E, James I, et al. (2003) Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 8, 617–626.
105Grinspoon S & Carr A (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352, 48–62.
106Jacobson DL, Knox T, Spiegelman D, et al. (2005) Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 40, 1837–1845.
107Miller KD, Jones E, Yanovski JA, et al. (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351, 871–875.
108Dinges WL, Chen D, Snell PG, et al. (2005) Regional body fat distribution in HIV-infected patients with lipodystrophy. J Investig Med 53, 15–25.
109Lo JC, Mulligan K, Tai VW, et al. (1998) “Buffalo hump” in men with HIV-1 infection. Lancet 351, 867–870.
110Palella FJ Jr, Chmiel JS, Riddler SA, et al. (2006) A novel pattern of lipoaccumulation in HIV-infected men. JAMA 296, 766–768.
111Guaraldi G, Orlando G, Squillace N, et al. (2007) Prevalence of and risk factors for pubic lipoma development in HIV-infected persons. J Acquir Immune Defic Syndr 45, 72–76.
112Cooper DA, Cordery DV, Reiss P, et al. (2011) The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy. HIV Med 12, 31–39.
113Grunfeld C, Kotler DP, Hamadeh R, et al. (1989) Hypertriglyceridemia in acquired immunodeficiency syndrome. Am J Med 86, 27–31.
114Grunfeld C, Kotler DP, Shigenaga JK, et al. (1991) Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 90, 154–162.
115Riddler SA, Smit E, Cole SR, et al. (2003) Impact of HIV infection and HAART on serum lipids in men. JAMA 289, 2978–2982.
116Tomažič J, Silič A, Karner P, et al. (2004) Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients. Wien Klin Wochenschr 116, 755–759.
117Lesi OA, Soyebi KS & Eboh CN (2009) Fatty liver and hyperlipidemia in a cohort of HIV-positive Africans on highly active antiretroviral therapy. J Natl Med Assoc 101, 151–155.
118Friis-Møller N, Weber R, Reiss P, et al. (2003) Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179–1193.
119Carr A, Samaras K, Chisholm DJ, et al. (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351, 1881–1883.
120Periard D, Telenti A, Sudre P, et al. (1999) Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100, 700–705.
121van Leth F, Phanuphak P, Stroes E, et al. (2004) Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 1, e19.
122Jones R, Sawleshwarkar S, Michailidis C, et al. (2005) Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 6, 396–402.
123Kosmiski LA, Miller HL & Klemm DJ (2006) In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival. Antivir Ther 11, 187–195.
124Ware LJ, Jackson AG, Wootton SA, et al. (2009) Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men. Br J Nutr. 102, 1038–1046.
125Monnerat BZ, Cerutti Junior C, Caniçali SC, et al. (2008) Clinical and biochemical evaluation of HIV-related lipodystrophy in an ambulatory population from the Hospital Universitário Cassiano Antonio de Morais, Vitória, ES, Brazil. Braz J Infect Dis 12, 364–368.
126Pernerstorfer-Schoen H, Jilma B, Perschler A, et al. (2001) Sex differences in HAART-associated dyslipidaemia. AIDS 15, 725–734.
127Gaillard T, Schuster D & Osei K (2009) Metabolic syndrome in black people of the African diaspora: the paradox of current classification, definition and criteria. Ethn Dis 19, Suppl. 2, .
128Foulkes AS, Wohl DA, Frank I, et al. (2006) Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med 3, e52.
129Guardiola M, Ferré R, Salazar J, et al. (2006) Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T → C gene variation. Clin Chem 52, 1914–1919.
130Fauvel J, Bonnet E, Ruidavets J-B, et al. (2001) An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 15, 2397–2406.
131Miserez AR, Muller PY, Barella L, et al. (2001) A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS 15, 2045–2049.
132Nolan D, Moore C, Castley A, et al. (2003) Tumour necrosis factor-α gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17, 121–123.
133Tarr Philip E, Taffé P, Bleiber G, et al. (2005) Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 191, 1419–1426.
134Abourizk NN, Lyons RW & Madden GM (1993) Transient state of NIDDM in a patient with AIDS. Diabetes Care 16, 931–933.
135Bradbury RA & Samaras K (2008) Antiretroviral therapy and the human immunodeficiency virus – improved survival but at what cost? Diabetes Obes Metab 10, 441–450.
136Eastone JA & Decker CA (1997) New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 127, 948.
137Visnergarwala F, Krause KL & Musher DM (1997) Severe diabetes associated with protease inhibitors. Ann Intern Med 127, 947.
138van Dieren S, Beulens JWJ, van der Schouw YT, et al. (2010) The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 17, Suppl. 1, s3–s8.
139Danaei G, Finucane MM, Lu Y, et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378, 31–40.
140Carr A, Hudson J, Chuah J, et al. (2001) HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 15, 1811–1822.
141Dubé MP, Parker RA, Tebas P, et al. (2005) Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 19, 1807–1818.
142Srivanich N, Ngarmukos C & Sungkanuparph S (2010) Prevalence of and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand. J Int Assoc Physicians AIDS Care 9, 358–361.
143Lee GA, Seneviratne T, Noor MA, et al. (2004) The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 18, 641–649.
144Woerle H, Mariuz PR, Meyer C, et al. (2003) Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52, 918–925.
145Tien PC, Schneider MF, Cole SR, et al. (2007) Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 21, 1739–1745.
146American Diabetes Association, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26, Suppl. 1, S5–S20.
147Wohl DA, McComsey G, Tebas P, et al. (2006) Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 43, 645–653.
148Crane HM, Grunfeld C, Harrington RD, et al. (2009) Lipoatrophy and lipohypertrophy are independently associated with hypertension. HIV Med 10, 496–503.
149de Arruda Junior ER, Lacerda HR, Moura LCRV, et al. (2010) Risk factors related to hypertension among patients in a cohort living with HIV/AIDS. Braz J Infect Dis 14, 281–287.
150Sattler FR, Qian D, Louie S, et al. (2001) Elevated blood pressure in subjects with lipodystrophy. AIDS 15, 2001–2010.
151Thiébaut R, El-Sadr WM, Friis-Møller N, et al. (2005) Data collection of adverse events of anti-HIV Drugs Study Group. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 10, 811–823.
152Franklin SS (2008) Beyond blood pressure: arterial stiffness as a new biomarker of cardiovascular disease. J Am Soc Hypertens 2, 140–151.
153van Vonderen MGA, Smulders YM, Stehouwer CDA, et al. (2009) Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 50, 153–161.
154Vigano A, Bedogni G, Cerini C, et al. (2010) Both HIV-infection and long-term antiretroviral therapy are associated with increased common carotid intima-media thickness in HIV-infected adolescents and young adults. Curr HIV Res 8, 411–417.
155Seaberg EC, Benning L, Sharrett AR, et al. (2010) Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke 41, 2163–2170.
156Shankar SS & Dubé MP (2004) Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. Cardiovasc Toxicol 4, 261–269.
157Stein JH, Klein MA, Bellehumeur JL, et al. (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104, 257–262.
158Dubé MP, Shen C, Mather KJ, et al. (2010) Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. AIDS Res Hum Retroviruses 26, 847–854.
159Torriani FJ, Komarow L, Parker RA, et al. (2008) Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 52, 569–576.
160Lefèvre C, Auclair M, Boccara F, et al. (2010) Premature senescence of vascular cells is induced by HIV protease inhibitors. Arterioscler Thromb Vasc Biol 30, 2611–2620.
161Coll B, Parra S, Alonso-Villaverde C, et al. (2006) HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine 34, 51–55.
162Calza L, Manfredi R, Pocaterra D, et al. (2008) Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. J Infect 57, 16–32.
163Kaplan RC, Kingsley LA, Gange SJ, et al. (2008) Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 22, 1615–1624.
164Henry K, Melroe H, Huebsch J, et al. (1998) Severe premature coronary artery disease with protease inhibitors. Lancet 351, 1328.
165Vittecoq D, Escaut L & Monsuez JJ (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351, 1959.
166Bozzette SA, Ake CF, Tam HK, et al. (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348, 702–710.
167Sabin CA, Worm SW, Weber R, et al. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371, 1417–1426.
168Barbaro G, Di Lorenzo G, Cirelli A, et al. (2003) An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretrovial therapy. Clin Ther 25, 2405–2418.
169Mallewa JE, Higgins SP, Garbett S, et al. (2009) Cardiovascular disease risk management in HIV patients, experiences from Greater Manchester. Int J STD AIDS 20, 425–426.
170Alvarez C, Salazar R, Galindez J, et al. (2010) Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis 14, 256–263.
171Schafer JJ, Short WR & Squires KE (2010) Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus. Pharmacotherapy 30, 1072–1083.
172Martin A, Amin J, Cooper D, et al. (2010) Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 24, 2657–2663.
173Schillaci G, Pucci G & De Socio GVL (2009) HIV infection and antiretroviral treatment: a two-hit model for arterial stiffness. Am J Hypertens 22, 817–818.
174Phillips AN, Carr A, Neuhaus J, et al. (2008) Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 13, 177–187.
175Calmy A, Gayet-Ageron A, Montecucco F, et al. (2009) HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 23, 929–939.
176Anderson KM, Odell PM, Wilson PWF, et al. (1991) Cardiovascular disease risk profiles. Am Heart J 121, 293–298.
177Friis-Møller N & Worm SW (2007) Editorial commentary: can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools? Clin Infect Dis 45, 1082–1084.
178May M, Sterne JA, Shipley M, et al. (2007) A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol 36, 1309–1318.
179Hammond E, McKinnon E & Nolan D (2010) Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 51, 591–599.
180Johnson JA, Albu JB, Engelson ES, et al. (2004) Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 286, E261–E271.
181Lagathu C, Eustace B, Prot M, et al. (2007) Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 12, 489–500.
182Kim RJ, Wilson CG, Wabitsch M, et al. (2006) HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity 14, 994–1002.
183Jan V, Cervera P, Maachi M, et al. (2004) Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 9, 555–564.
184Sievers M, Walker UA, Sevastianova K, et al. (2009) Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse transcriptase inhibitor-associated lipodystrophy. J Infect Dis 200, 252–262.
185Bastard J-P, Maachi M, van Nhieu JT, et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87, 2084–2089.
186Domingo P, Vidal F, Domingo JC, et al. (2005) Tumour necrosis factor α in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 35, 771–780.
187Kovsan J, Ben-Romano R, Souza SC, et al. (2007) Regulation of adipocyte lipolysis by degradation of the perilipin protein. J Biol Chem 282, 21704–21711.
188Mallewa JE, Wilkins E, Vilar J, et al. (2008) HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother 62, 648–660.
189Rudich A, Ben-Romano R, Etzion S, et al. (2005) Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 183, 75–88.
190Zhang HH, Halbleib M, Ahmad F, et al. (2002) Tumor necrosis factor-α stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51, 2929–2935.
191Rydén M, Arvidsson E, Blomqvist L, et al. (2004) Targets for TNF-α-induced lipolysis in human adipocytes. Biochem Biophys Res Commun 318, 168–175.
192Adler-Wailes D, Guiney EL, Koo J, et al. (2008) Effects of ritonavir on adipocyte gene expression: evidence for a stress-related response. Obesity 16, 2379–2387.
193Giralt M, Domingo P, Guallar JP, et al. (2006) HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther 11, 729–740.
194Bezante GP, Briatore L, Rollando D, et al. (2009) Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage. Nutr Metab Cardiovasc Dis 19, 277–282.
195Körner A, Wabitsch M, Seidel B, et al. (2005) Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight. Biochem Biophys Res Commun 337, 540–550.
196Pacenti M, Barzon L, Favaretto F, et al. (2006) Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. AIDS 20, 1691–1705.
197Lindegaard B, Keller P, Bruunsgaard H, et al. (2004) Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 135, 273–279.
198Sevastianova K, Sutinen J, Kannisto K, et al. (2008) Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 295, E85–E91.
199Caron M, Auclair M, Lagathu C, et al. (2004) The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 18, 2127–2136.
200Grigem S, Fischer-Posovszky P, Debatin KM, et al. (2005) The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes. Horm Metab Res 37, 602–609.
201Kim MJ, Leclercq PE, Lanoy E, et al. (2007) A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir Ther 12, 1273–1283.
202Villarroya F, Domingo P & Giralt M (2010) Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. BBA-Mol Cell Biol L 1801, 392–399.
203Venhoff N, Setzer B, Melkaoui K, et al. (2007) Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 12, 1075–1085.
204Birkus G, Hitchcock MJM & Cihlar T (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46, 716–723.
205Viengchareun S, Caron M, Auclair M, et al. (2007) Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antivir Ther 12, 919–929.
206Walker UA, Setzer B & Venhoff N (2002) Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16, 2165–2173.
207Ribera E, Paradiñeiro JC, Curran A, et al. (2008) Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST Study). HIV Clin Trials 9, 407–417.
208Caron M, Auclairt M, Vissian A, et al. (2008) Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther 13, 27–38.
209Walker UA, Auclair M, Lebrecht D, et al. (2006) Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 11, 25–34.
210Sension M, de Andrade Neto JL, Grinsztejn B, et al. (2009) Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 51, 153–162.
211Sivakumar T, Mechanic O, Fehmie D, et al. (2011) Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Med 12, 453–462.
212Tungsiripat M & Aberg JA (2005) Dyslipidemia in HIV patients. Clev Clin J Med 72, 1113–1120.
213Dubé MP, Stein JH, Aberg JA, et al. (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37, 613–627.
214Fichtenbaum C, Gerber JG, Rosenkranz SL, et al. (2002) Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16, 569–577.
215Feldt T, Oette M, Kroidl A, et al. (2006) Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome. Infection 34, 55–61.
216Raboud JM, Diong C, Carr A, et al. (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11, 39–50.
217Hadigan C, Corcoran C, Basgoz N, et al. (2000) Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 284, 472–477.
218van Wijk JPH, Hoepelman AIM, de Koning EJP, et al. (2011) Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. Arterioscler Thromb Vasc Biol 31, 228–233.
219Jiménez-Nácher I, Alvarez E, Morello J, et al. (2011) Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol 7, 457–477.
220Martínez E (2011) Disorders of fat partitioning in treated HIV-infection. Best Prac Res Clin Endocrinol Metab 25, 415–427.
221van Vonderen MGA, Gras L, Wit F, et al. (2009) Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir. HIV Clin Trials 10, 168–180.
222Psaty BM & Furberg CD (2007) Rosiglitazone and cardiovascular risk. N Engl J Med 356, 2522–2524.
223Hultman CS, McPhail LE, Donaldson JH, et al. (2007) Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy. Ann Plas Surg 58, 255–263.
224Warren A & Borud LJ (2008) Excisional lipectomy for HIV-associated cervicodorsal lipodystrophy. Aesthet Surg J 28, 147–152.
225Moreno S, Miralles C, Negredo E, et al. (2009) Disorders of body fat distribution in HIV-1-infected patients. AIDS Rev 11, 126–134.
226Skeie L, Bugge H, Negaard A, et al. (2010) Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study. HIV Med 11, 170–177.
227Dollfus C, Blanche S, Trocme N, et al. (2009) Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents. HIV Med 10, 263–268.
228Narciso P, Bucciardini R, Tozzi V, et al. (2009) Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study. AIDS Res Hum Retroviruses 25, 979–987.
229Guaraldi G, Squillace N, De Fazio D, et al. (2009) Heterologous fat transplantation for the treatment of HIV-related facial lipoatrophy. Ann Intern Med 150, 61–63.
230Terry L, Sprinz E, Stein R, et al. (2006) Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc 38, 411–417.
231Roubenoff R, Weiss L, McDermott A, et al. (1999) A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 13, 1373–1375.
232Jones SP, Doran DA, Leatt PB, et al. (2001) Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 15, 2049–2051.
233Yarasheski KE & Roubenoff R (2001) Exercise treatment for HIV-associated medical and anthropomorphic complications. Exerc Sport Sci Rev 29, 170–174.
234Fillipas S, Cherry CL, Cicuttini F, et al. (2010) The effects of exercise training on metabolic and morphological outcomes for people living with HIV: a systematic review of randomised controlled trials. HIV Clin Trials 11, 270–282.
235Florindo AA, Rosario Dias de Oliveira Latorre Mdo R, Jaime PC, et al. (2007) Leisure time physical activity prevents accumulation of central fat in HIV/AIDS subjects on highly active antiretroviral therapy. Int J STD AIDS 18, 692–696.
236Yarasheski KE, Tebas P, Stanerson B, et al. (2001) Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol 90, 133–138.
237Lindegaard B, Hansen T, Hvid T, et al. (2008) The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab 93, 3860–3869.
238Hadigan C (2003) Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy. Clin Infect Dis 37, Suppl. 2, S101–S104.
239Gavrila A, Tsiodras S, Doweiko J, et al. (2003) Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. Clin Infect Dis 36, 1593–1601.
240Batterham MJ, Garsia R & Greenop PA (2000) Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy ‘Diet FRS Study’. AIDS 14, 1839–1843.
241Samaras K, Wand H, Law M, et al. (2009) Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism. Curr HIV Res 7, 454–461.
242Barrios A, Blanco F, Garcia-Benayas T, et al. (2002) Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 16, 2079–2081.
243Ng G, Chan U, Li P, et al. (2011) Can a Mediterranean diet reduce the effect of lipodystrophy syndrome in people living with HIV? A pilot randomised controlled trial. Sex Health 8, 43–51.
244Roubenoff R, Schmitz H, Bairos L, et al. (2002) Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 34, 390–393.
245Vázquez C, Reyes R, Alcaraz F, et al. (2006) Eucaloric substitution of medium chain triglycerides for dietary long chain fatty acids improves body composition and lipid profile in a patient with human immunodeficiency virus lipodystrophy. Nutr Hosp 21, 552–555.
246Famularo G, Moretti S, Marcellini S, et al. (1997) Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 11, 185–190.
247Benedini S, Perseghin G, Terruzzi I, et al. (2009) Effect of l-acetylcarnitine on body composition in HIV-related lipodystrophy. Horm Metab Res 41, 840–845.
248McComsey GA, O'Riordan M, Setzer B, et al. (2007) Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr 62, 1031–1037.
249Calmy A, Bloch M, Wand H, et al. (2010) No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med 11, 493–501.
250Sutinen J, Walker UA, Sevastianova K, et al. (2007) Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 12, 97–105.
251Kamanna VS & Kashyap ML (2008) Mechanism of action of niacin. Am J Cardiol 101, Suppl. 1, S20–S26.
252Balasubramanyam A, Coraza I, Smith EO, et al. (2011) Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of “heart positive,” a randomized, controlled trial. J Clin Endocrinol Metab 96, 2236–2247.
253Kosmiski LA, Bessesen DH, Stotz SA, et al. (2007) Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism. Metabolism 56, 289–295.
254Kosmiski LA, Kuritzkes DR, Sharp TA, et al. (2003) Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. Metabolism 52, 620–625.
255Kosmiski LA, Bessesen DH, Stotz SA, et al. (2007) Short-term overfeeding increases resting energy expenditure in patients with HIV lipodystrophy. Am J Clin Nutr 86, 1009–1015.
256Razzini E & Baronzio GF (1993) Omega-3 fatty acids as coadjuvant treatment in AIDS. Med Hypotheses 41, 300–305.
257De Truchis P, Kirstetter M, Perier A, et al. (2007) Reduction in triglyceride level with n-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr 44, 278–285.
258Wohl DA, Tien HC, Busby M, et al. (2005) Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 41, 1498–1504.
259Gerber JG, Kitch DW, Fichtenbaum CJ, et al. (2008) Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 47, 459–466.
260Manfredi R, Calza L & Chiodo F (2004) Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. J Acquir Immune Defic Syndr 36, 878–880.
261Baril J, Kovacs CM, Trottier S, et al. (2007) Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia. HIV Clin Trials 8, 400–411.
262Ranieri R (2007) Effect of omega-3 fatty acids on the lipid structure of HIV-positive patients on antiretroviral therapy: personal observation of 20 subjects (article in Italian). Infez Med 15, 237–241.
263Hellerstein MK, Wu K, McGrath M, et al. (1996) Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: relation to indices of cytokine production. J Acquir Immune Defic Syndr Hum Retrovirol 11, 258–270.
264Carter VM, Woolley I, Jolley D, et al. (2006) A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sex Health 3, 287–290.
265Virgili N, Farriol M, Castellanos JM, et al. (1997) Evaluation of immune markers in asymptomatic AIDS patients receiving fish oil supplementation. Clin Nutr 16, 257–261.
266Normén L, Yip B, Montaner J, et al. (2007) Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets. HIV Med 8, 346–356.
267Calder PC (2002) Dietary modification of inflammation with lipids. Proc Nutr Soc 61, 345–358.
268Weldon SM, Mullen AC, Loscher CE, et al. (2007) Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 18, 250–258.
269Mullen A, Loscher CE & Roche HM (2010) Anti-inflammatory effects of EPA and DHA are dependent upon time and dose–response elements associated with LPS stimulation in THP-1-derived macrophages. J Nutr Biochem 21, 444–450.
270Pichard C, Sudre P, Karsegard V, et al. (1998) A randomized double-blind controlled study of 6 months of oral nutritional supplementation with arginine and Ω-3 fatty acids in HIV-infected patients. Swiss HIV Cohort Study. AIDS 12, 53–63.
271Bell S, Chavali S, Bistrian BR, et al. (1996) Dietary fish oil and cytokine and eicosanoid production during human immunodeficiency virus infection. JPEN J Parenter Enteral Nutr 20, 43–49.